Neurorehabilitation News

Neurogene Inc. announced the FDA has granted clearance to its investigational new drug application for NGN-401, an adeno-associated virus gene therapy candidate for treating Rett syndrome in female pediatric patients.

Individuals with mental disorders who attempted suicide were reported to have impaired or abnormal social decision-making, evidenced by neuro-electrophysiological activity, according to a study published in BMC Psychiatry.

The most common neurological manifestations of COVID-19 for individuals living in Saudi Arabia were headache, changes in smell and taste, muscle pain, loss of consciousness and seizures, which were similar to global reports.

The FDA has granted fast track designation to Avidity Biosciences Inc. for its novel RNA therapeutic AOC 1020, an antibody oligonucleotide conjugate being studied for the treatment of facioscapulohumeral muscular dystrophy.

Myrtelle Inc. announced updated findings of the open-label phase 1/2 clinical trial of its recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease, a fatal genetic disorder in children.

A team of three Ohio research companies has won a seat on an 8-year, $149 million indefinite delivery, indefinite quantity contract vehicle for the National Institute of Neurological Disorders and Stroke.

Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in infants with spinal muscular atrophy, according to a poster presented at the International Scientific Congress on Spinal Muscular Atrophy.

As the world continues to grapple with effects of the COVID-19 pandemic, individuals around the globe are still dealing with symptoms of SARS-CoV-2 infection for months, even years, after their initial infection.

Singing may be a potential tool to promote communicative and psychosocial outcomes among patients with post-stroke aphasia, researchers reported in Brain Communications.

People experiencing persistent post-concussion symptoms were at a higher risk for depressive symptoms, researchers reported in JAMA Network Open.